OR WAIT null SECS
Click here to read the articles and download the PDF
Michael Bailey, CEO of AVEO Oncology, discusses how his ultimate leadership path in biotech—the setbacks and “long slog of ups and downs”—continues to shape a patient-focused mission.
Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.
Melissa Thompson, Alcon’s head of global corporate social responsibility and president of the Alcon Foundation and Alcon Cares, discusses her career commitment to CSR and how COVID-19 has impacted the organization’s efforts to enrich global communities.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
April 09, 2021
A picture of wide manufacturing violations appears in a recently disclosed FDA form 483 report on a site visit to Emergent’s Baltimore vaccine plant.
April 08, 2021
Ahmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.
Updated programs supporting the development and review of prescription medicines are being readied for approval by federal agencies and ultimately by Congress
In an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Audio platforms provide new opportunities for pharma.
April 07, 2021
Pharm Exec speaks to David Hysong, founder and Chief Executive Officer of SHEPHERD, whose mission, stated simply, is ”to make the drugs other companies won’t make to save lives others aren’t saving.”
April 06, 2021
André Sode, CEO of Liva Healthcare, talks about Liva’s collaboration with Amgen to co-create an innovative digital tele-rehabilitation solution called Rehab+.
April 02, 2021
New American Jobs Plan set to be funded by corporate taxes will affect biopharma industry.
April 01, 2021
Uche Iloeje, Vice President medical affairs Mirdametenib at SpringWorks Therapeutics, shares his experience after he became stranded in Nigeria for five months and the valuable leadership lessons he learned.
Next tier of markets is poised to ascend and offer valuable opportunities to both investors and occupiers.
March 31, 2021
Healthcare providers across Canada will be able to capture adverse events in the Auxita platform through integration with MyMeds&Me’s pharmacovigilance SaaS platform, Reportum.
This month brings the IR35 tax reform on the UK’s private sector. How will it affect the pharma industry?
March 30, 2021
New product expands outreach of medical affairs organizations.
March 29, 2021
With Sen. Bernie Sanders leading the charge on Capitol Hill, the campaign to limit U.S. outlays for prescription drugs has accelerated.
It’s important that care for people with pre-existing conditions or at risk from serious diseases does not fall by the wayside.
March 26, 2021
The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
March 25, 2021
Owen Mumford Pharmaceutical Services report details impressions and predictions of industry professionals on the future of virtual events.
March 24, 2021
FDA is reviewing the record of its accelerated approval program following recent withdrawals of certain key indications for several leading cancer therapies, based on the failure of post-approval studies to document extended benefits of treatment.
A coalition of biopharma and technology leaders have announced a new strategic collaboration to promote new and updated standards for advanced therapies.
Pharma and life science companies can reduce time to market by optimizing regulatory content management and submission processes.
Research shows ESG performance is strongly predictive of long-term value creation and financial performance, when a sector-specific approach is maintained.
On examination of the challenge and strategies, lack of adherence is in and of itself a preventable disease.
NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
March 23, 2021
Henry McNamara, Senior Vice President and General Manager, Oracle Health Sciences, reviews the lessons that the industry has learned over the last year and looks at what lies ahead for pharma in 2021.
Assessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.
March 22, 2021
Dr. Andrew (Drew) Otoo talks about how pharma employees can elevate their own value propositions.
Agile Therapeutics' CEO Al Altomari talks about his decade of leadership at the company and the process of launching a new product during COVID-19.
Aligning meaningful messages across the appropriate platforms headline ways marketers can enhance communication with physicians.
Moving beyond the pill to extend the value being delivered to patients.
Mitigating potential risk for stakeholders in light of latest Sunshine Act developments.
